Is NCT07382739 recruiting in Houston, TX?

Yes, NCT07382739 is currently recruiting participants at its Houston, TX location. This phase 2 clinical trial is actively enrolling qualified participants.

How do I join the phase 2 clinical trial in Houston?

To join this clinical trial in Houston, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Houston clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Phase 2 Clinical Trial in Houston, TX

Who Can Participate

Inclusion Criteria

RRMM exposed to IMID, PI, anti-CD38 mAb, relapsed or refractory to at least one prior line of therapy (LOT), progressed on or after the last regimen:

Relapsed disease: progressive disease (PD) \>60 days after cessation of prior therapy

Refractory disease: PD \<=60 days after cessation of prior therapy, \<25% reduction in paraprotein (monoclonal protein \[M-protein\] or serum free light chains \[sFLC\]) or measurements of EMD/PMD

Diagnosis of relapsed or refractory multiple myeloma as indicated by progression by IMWG criteria

At least one locus of EMD or PMD present on imaging (either PET/CT or magnetic resonance imaging \[MRI\]):

EMD: extramedullary plasmacytoma, not a contiguous extension from a bone lesion.

PMD: paraskeletal plasmacytoma, contiguous extension from a bone lesion At least one locus of EMD/PMD that was not previously radiated and can be treated with radiation

Hematology (supportive care is allowed, including transfusions and granulocyte colony stimulating factor (G-CSF), if cytopenia is deemed secondary to myeloma disease burden):

Hemoglobin (Hgb) \>=7g/dL

Platelet\>=50K/uL

Absolute neutrophil count (ANC) \>=0.75K/uL

Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) \<=2.5 x upper

limit of normal (ULN)

Total bilirubin (TBili) \<=1.5ULN (except for a known history of Gilbert syndrome)

Creatinine clearance (CrCL) \>=30mL/min/1.73m2

Eastern Cooperative Oncology Group Performance Status (ECOG PS) \<=2, unless ECOG PS due to pain/morbidity secondary to underlying myeloma disease, with the potential of improved ECOG PS to \<=2.

All participants must be either

Not of childbearing potential, or

Practicing at least 1 highly effective method of contraception until 6 months after the last dose of study treatment.

Childbearing age female participantsmust have a negative serum pregnancy test at screening and must agree to further pregnancy tests during the study.

Exclusion Criteria

Prior or concurrent exposure to any of the following in the specified time frame prior to the first dose of Elra treatment:

Within 14 days or at least 5 half-lives, whichever is less, of any investigational treatment

Within 7 days of IMIDs, PI, anti-CD38 mAb, or cytotoxic systemic myeloma therapies

Within 12 weeks of autologous stem-cell therapy (ASCT) or 6 months of AlloSCT and has to be off immunosuppressive agents \>=42 days without signs of graft versus host disease (GVHD)

Within 2 weeks of major surgery

Within 6 months of cerebrovascular accident (CVA) events

Waldenstrom, POEMS, Amyloidosis, ongoing plasma cell leukemia (PCL)

History of Human Immunodeficiency Virus (HIV)

Active, uncontrolled HBV infection despite antiviral therapy.

Uncontrolled cardiac, pulmonary, gastrointestinal (GI), hepatic, renal, central nervous system(CNS) diseases not due to myeloma, at the discretion of investigator, that are not a candidate for T cell engager (TCE) therapy

Uncontrolled or recurrent infections

Autoimmune disease requiring systemic treatment (except for low dose steroids, equivalent to 10mg/day or less of prednisone)

Disabling psychiatric conditions, substance abuse (alcohol, or drug), dementia, altered mental status

Any other active malignancies within 5 years of completing treatment (with the exception of hormonal therapies for breast or prostate cancer) and \>minimal risk of recurrence

Myelodysplastic syndromes (MDS)

Any issues that may impair the ability of the participant to receive or tolerate the planned treatment, to understand the informed consent, or any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant or that would prevent, limit, or confound the protocol specified assessments.

History of allergic reactions attributed to compounds of similar chemical or biologic composition to Elra or other agents used in study.

History or possible non-compliance with recommended treatments

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Houston?

Yes, this clinical trial (NCT07382739) has an active research site in Houston, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Phase 2 Treatment Options in Houston, TX

If you're searching for phase 2 treatment options in Houston, TX, this clinical trial (NCT07382739) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Houston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced phase 2 specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all phase 2 clinical trials near you to find additional studies recruiting in your area.

Phase 2 Clinical Trial in Houston, TX

Expert Care in Houston

IRB Approved

No-Cost Care

Apply for This Houston Location

Why Participate?

Simple Process

About This Phase 2 Study in Houston